Alcohol Addiction - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 133 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Alcohol Addiction - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Alcohol Addiction - Pipeline Review, H1 2016', provides an overview of the Alcohol Addiction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
- The report reviews pipeline therapeutics for Alcohol Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Alcohol Addiction therapeutics and enlists all their major and minor projects
- The report assesses Alcohol Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Alcohol Addiction

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Alcohol Addiction Overview 10
Therapeutics Development 11
Pipeline Products for Alcohol Addiction - Overview 11
Pipeline Products for Alcohol Addiction - Comparative Analysis 12
Alcohol Addiction - Therapeutics under Development by Companies 13
Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes 15
Alcohol Addiction - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Alcohol Addiction - Products under Development by Companies 19
Alcohol Addiction - Products under Investigation by Universities/Institutes 21
Alcohol Addiction - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
Addex Therapeutics Ltd 23
Adial Pharmaceuticals, LLC 24
Arbutus Biopharma Corporation 25
Astraea Therapeutics, LLC 26
AstraZeneca Plc 27
Bionex Pharmaceuticals LLC 28
Curemark, LLC 29
Eli Lilly and Company 30
Ethypharm S.A. 31
Euthymics Bioscience, Inc. 32
Foresee Pharmaceuticals, LLC 33
H. Lundbeck A/S 34
Indivior Plc 35
Johnson & Johnson 36
Kyorin Pharmaceutical Co., Ltd. 37
Lohocla Research Corporation 38
Omeros Corporation 39
Pfizer Inc. 40
RTI International 41
SK Biopharmaceuticals Co., Ltd. 42
Tonix Pharmaceuticals Holding Corp. 43
VM Discovery, Inc. 44
XenoPort, Inc. 45
Zynerba Pharmaceuticals, Inc. 46
Alcohol Addiction - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 52
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
(disulfiram + selegiline) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
A-705253 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ABT-436 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ADX-71441 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
amitifadine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
arbaclofen placarbil - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AT-1001 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
baclofen - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
carisbamate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
CERC-501 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
CM-1212 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Drug to Inhibit Triple Reuptake for Alcohol Dependence - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
FP-007 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
gabapentin enacarbil XR - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
GET-73 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ibudilast - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
JDTic - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
JNJ-5234801 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
nalmefene - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
naltrexone hydrochloride - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
naltrexone hydrochloride - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
odelepran hydrochloride - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
OMS-527 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ondansetron hydrochloride - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
PF-04457845 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
saracatinib difumarate - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecule to Antagonize Ghrelin Receptor for Alcoholism - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
TKM-ALDH2 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
VMD-2202 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Alcohol Addiction - Recent Pipeline Updates 103
Alcohol Addiction - Dormant Projects 121
Alcohol Addiction - Discontinued Products 124
Alcohol Addiction - Product Development Milestones 125
Featured News & Press Releases 125
Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501 125
Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting 125
Oct 01, 2015: XenoPort Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director 126
Jun 30, 2015: MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 in Alcohol Dependence 127
Jun 25, 2015: XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder 127
Jun 24, 2015: MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting 128
Jan 11, 2015: XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder 128
Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder 129
Nov 26, 2014: Biotie: UK's Nice Issues Positive Final Guidance For Selincro 130
Nov 26, 2014: Drug recommended to help cut drink dependence 130
Appendix 132
Methodology 132
Coverage 132
Secondary Research 132
Primary Research 132
Expert Panel Validation 132
Contact Us 132
Disclaimer 133

List of Tables
Number of Products under Development for Alcohol Addiction, H1 2016 11
Number of Products under Development for Alcohol Addiction - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Development by Companies, H1 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Alcohol Addiction - Pipeline by AbbVie Inc., H1 2016 22
Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H1 2016 23
Alcohol Addiction - Pipeline by Adial Pharmaceuticals, LLC, H1 2016 24
Alcohol Addiction - Pipeline by Arbutus Biopharma Corporation, H1 2016 25
Alcohol Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2016 26
Alcohol Addiction - Pipeline by AstraZeneca Plc, H1 2016 27
Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2016 28
Alcohol Addiction - Pipeline by Curemark, LLC, H1 2016 29
Alcohol Addiction - Pipeline by Eli Lilly and Company, H1 2016 30
Alcohol Addiction - Pipeline by Ethypharm S.A., H1 2016 31
Alcohol Addiction - Pipeline by Euthymics Bioscience, Inc., H1 2016 32
Alcohol Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 33
Alcohol Addiction - Pipeline by H. Lundbeck A/S, H1 2016 34
Alcohol Addiction - Pipeline by Indivior Plc, H1 2016 35
Alcohol Addiction - Pipeline by Johnson & Johnson, H1 2016 36
Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 37
Alcohol Addiction - Pipeline by Lohocla Research Corporation, H1 2016 38
Alcohol Addiction - Pipeline by Omeros Corporation, H1 2016 39
Alcohol Addiction - Pipeline by Pfizer Inc., H1 2016 40
Alcohol Addiction - Pipeline by RTI International, H1 2016 41
Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 42
Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 43
Alcohol Addiction - Pipeline by VM Discovery, Inc., H1 2016 44
Alcohol Addiction - Pipeline by XenoPort, Inc., H1 2016 45
Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 46
Assessment by Monotherapy Products, H1 2016 47
Assessment by Combination Products, H1 2016 48
Number of Products by Stage and Target, H1 2016 50
Number of Products by Stage and Mechanism of Action, H1 2016 53
Number of Products by Stage and Route of Administration, H1 2016 55
Number of Products by Stage and Molecule Type, H1 2016 57
Alcohol Addiction Therapeutics - Recent Pipeline Updates, H1 2016 103
Alcohol Addiction - Dormant Projects, H1 2016 121
Alcohol Addiction - Dormant Projects (Contd..1), H1 2016 122
Alcohol Addiction - Dormant Projects (Contd..2), H1 2016 123
Alcohol Addiction - Discontinued Products, H1 2016 124